Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01).
de Groot S, Charehbili A, van Laarhoven HW, Mooyaart AL, Dekker-Ensink NG, van de Ven S, Janssen LG, Swen JJ, Smit VT, Heijns JB, Kessels LW, van der Straaten T, Böhringer S, Gelderblom H, van der Hoeven JJ, Guchelaar HJ, Pijl H, Kroep JR; Dutch Breast Cancer Research Group. de Groot S, et al. Among authors: charehbili a. Breast Cancer Res. 2016 Jan 6;18(1):3. doi: 10.1186/s13058-015-0663-3. Breast Cancer Res. 2016. PMID: 26738606 Free PMC article. Clinical Trial.
Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01).
Charehbili A, van de Ven S, Smit VT, Meershoek-Klein Kranenbarg E, Hamdy NA, Putter H, Heijns JB, van Warmerdam LJ, Kessels L, Dercksen M, Pepels MJ, Maartense E, van Laarhoven HW, Vriens B, Wasser MN, van Leeuwen-Stok AE, Liefers GJ, van de Velde CJ, Nortier JW, Kroep JR; Dutch Breast Cancer Research Group (BOOG). Charehbili A, et al. Ann Oncol. 2014 May;25(5):998-1004. doi: 10.1093/annonc/mdu102. Epub 2014 Feb 27. Ann Oncol. 2014. PMID: 24585721 Free article. Clinical Trial.
Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients--a phase II trial.
Fontein DB, Charehbili A, Nortier JW, Meershoek-Klein Kranenbarg E, Kroep JR, Putter H, van Riet Y, Nieuwenhuijzen GA, de Valk B, Terwogt JM, Algie GD, Liefers GJ, Linn S, van de Velde CJ. Fontein DB, et al. Among authors: charehbili a. Eur J Cancer. 2014 Sep;50(13):2190-200. doi: 10.1016/j.ejca.2014.05.010. Epub 2014 Jun 23. Eur J Cancer. 2014. PMID: 24970786 Clinical Trial.
Accuracy of MRI for treatment response assessment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer.
Charehbili A, Wasser MN, Smit VT, Putter H, van Leeuwen-Stok AE, Meershoek-Klein Kranenbarg WM, Liefers GJ, van de Velde CJ, Nortier JW, Kroep JR. Charehbili A, et al. Eur J Surg Oncol. 2014 Oct;40(10):1216-21. doi: 10.1016/j.ejso.2014.07.036. Epub 2014 Aug 8. Eur J Surg Oncol. 2014. PMID: 25150151 Clinical Trial.
Optical mammography using diffuse optical spectroscopy for monitoring tumor response to neoadjuvant chemotherapy in women with locally advanced breast cancer.
Schaafsma BE, van de Giessen M, Charehbili A, Smit VT, Kroep JR, Lelieveldt BP, Liefers GJ, Chan A, Löwik CW, Dijkstra J, van de Velde CJ, Wasser MN, Vahrmeijer AL. Schaafsma BE, et al. Among authors: charehbili a. Clin Cancer Res. 2015 Feb 1;21(3):577-84. doi: 10.1158/1078-0432.CCR-14-0736. Epub 2014 Dec 3. Clin Cancer Res. 2015. PMID: 25473002 Clinical Trial.
Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.
Onstenk W, Kraan J, Mostert B, Timmermans MM, Charehbili A, Smit VT, Kroep JR, Nortier JW, van de Ven S, Heijns JB, Kessels LW, van Laarhoven HW, Bos MM, van de Velde CJ, Gratama JW, Sieuwerts AM, Martens JW, Foekens JA, Sleijfer S. Onstenk W, et al. Among authors: charehbili a. Mol Cancer Ther. 2015 Mar;14(3):821-7. doi: 10.1158/1535-7163.MCT-14-0653. Epub 2014 Dec 31. Mol Cancer Ther. 2015. PMID: 25552367 Clinical Trial.
Thyroid function alters during neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01).
de Groot S, Janssen LG, Charehbili A, Dijkgraaf EM, Smit VT, Kessels LW, van Bochove A, van Laarhoven HW, Meershoek-Klein Kranenbarg E, van Leeuwen-Stok AE, van de Velde CJ, Putter H, Nortier JW, van der Hoeven JJ, Pijl H, Kroep JR. de Groot S, et al. Among authors: charehbili a. Breast Cancer Res Treat. 2015 Jan;149(2):461-6. doi: 10.1007/s10549-014-3256-4. Epub 2015 Jan 4. Breast Cancer Res Treat. 2015. PMID: 25556355 Free PMC article. Clinical Trial.
The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis.
Engels CC, Charehbili A, van de Velde CJ, Bastiaannet E, Sajet A, Putter H, van Vliet EA, van Vlierberghe RL, Smit VT, Bartlett JM, Seynaeve C, Liefers GJ, Kuppen PJ. Engels CC, et al. Among authors: charehbili a. Breast Cancer Res Treat. 2015 Feb;149(3):587-96. doi: 10.1007/s10549-015-3269-7. Epub 2015 Jan 24. Breast Cancer Res Treat. 2015. PMID: 25616355 Free PMC article. Clinical Trial.
Disorganised stroma determined on pre-treatment breast cancer biopsies is associated with poor response to neoadjuvant chemotherapy: Results from the NEOZOTAC trial.
Dekker TJ, Charehbili A, Smit VT, ten Dijke P, Kranenbarg EM, van de Velde CJ, Nortier JW, Tollenaar RA, Mesker WE, Kroep JR. Dekker TJ, et al. Among authors: charehbili a. Mol Oncol. 2015 Jun;9(6):1120-8. doi: 10.1016/j.molonc.2015.02.001. Epub 2015 Feb 14. Mol Oncol. 2015. PMID: 25735561 Free PMC article. Clinical Trial.
28 results